OncoMatch/Clinical Trials/NCT07638007
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Is NCT07638007 recruiting? Yes, currently enrolling (Jul 2026).
This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Prior therapy
Cannot have received: TKI therapy
Participants must have no history of TKI therapy
Cannot have received: cytotoxic chemotherapy
Exception: prior use of hydroxyurea for the treatment of CML or CLL as well as treatment with obinutuzumab or rituximab concurrent with TKI therapy for CLL
Participants must have no history of cytotoxic chemotherapy ... within the past 5 years
Cannot have received: immune checkpoint inhibitor therapy
Exception: prior use of hydroxyurea for the treatment of CML or CLL as well as treatment with obinutuzumab or rituximab concurrent with TKI therapy for CLL
Participants must have no history of ... immune checkpoint inhibitor therapy ... within the past 5 years
Cannot have received: hormonal therapy
Exception: prior use of hydroxyurea for the treatment of CML or CLL as well as treatment with obinutuzumab or rituximab concurrent with TKI therapy for CLL
Participants must have no history of ... hormonal therapy ... within the past 5 years
Cannot have received: biologic therapy
Exception: prior use of hydroxyurea for the treatment of CML or CLL as well as treatment with obinutuzumab or rituximab concurrent with TKI therapy for CLL
Participants must have no history of ... biologic therapy ... within the past 5 years
Cannot have received: radiotherapy
Exception: prior use of hydroxyurea for the treatment of CML or CLL as well as treatment with obinutuzumab or rituximab concurrent with TKI therapy for CLL
Participants must have no history of ... radiotherapy within the past 5 years
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Rochester NCORP Research Base · Rochester, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07638007 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TKI therapy, cytotoxic chemotherapy, immune checkpoint inhibitor therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify